Dear editor,
Intra-arterial thrombectomy (IAT) is a highly effective treatment for large artery occlusive stroke (LAO) with good recanalization rates of >80%. [1] [2] [3] To inform a model to estimate the impact of different service configurations for IAT delivery, a survey was emailed in December 2014 to clinical leads of all 24 interventional neuroradiology (INR) services in England (2014 population $54 million).
Eighteen centers responded (75% response)-these provide INR services covering $80% of the population with a median of three INRs. Ten centers (56%) had formal IAT protocols, and six (33%) protocols for inter-hospital transfers. No centers reported delivery of IAT by non-INRs. The majority delivered IAT only on weekdays (n ¼ 12, 67%), and three had no regular provision at all. One center had 24/7 IAT provision and two centers over seven days during normal hours. We identified variation in patient selection criteria for IAT; anesthetic technique and primary IAT strategy (see Table 1 ). Routine use of imaging scoring systems varied widely across centers.
Modal preferences for future IAT provision were delivery by INRs, in a network where necessary, (n ¼ 13, 72%); drip and ship inter-hospital transfers (n ¼ 17, 94%); and anesthetic support via crash type systems (n ¼ 14, 78%). There was clear support for centralization of IAT provision into large hyperacute stroke units associated with neuroscience units (n ¼ 16, 89%).
A quarter of centers in England providing INR services failed to respond. However, only one of the six non-responders is known to have substantial IAT activity. 4 Our findings are similar to those reported for France in 2014 5 except for higher 24/7 provision (81%) in France. Overall, our survey shows large variability between services in preferred IAT protocols and delivery, which future guideline groups need to consider, and major challenges in moving to a 24/7 provision of IAT across England.
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